EAGLE - An example for a diabetes simulation model;Krankheitsmodell am beispiel diabetes - Das EAGLE-modell

Gesundheitsokonomie und Qualitatsmanagement

Volumn 10, Issue SUPPL. 2, 2005, Pages

  Casciano, Roman N ^a   Walzer, S ^a   Muller E ^a  

^a Analytica International   (Germany)

Author keywords

Cost effectiveness; Diabetes mellitus; Health economics; Modelling; Simulation

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE MODEL; ECONOMIC EVALUATION; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; MATHEMATICAL MODEL; PARAMETER; PROSPECTIVE STUDY; REVIEW; SIMULATION; STATISTICAL MODEL; UNITED KINGDOM; VALIDATION PROCESS;

EID: 24744451225     PISSN: 14322625     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-858484     Document Type: Review

References (17)

1. Clarke PM, Gray AM, Briggs A et al. UK Prospective Diabetes Study (UKDPS) Group. A model to estimate the lifetime health outcomes of patients with type 2 diabetes mellitus: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004; 47: 1747-1759
2. Klein R, Klein BE, Moss SE et al. Prevalence of diabetes mellitus in southern Wisconsin. Am J Epidemiol 1984; 119: 54-61
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986
4. The UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853
5. World Health Organisation life tables for France, Germany, Spain, UK, USA. http://www3.who.int/whosis/life/life_tables/life_tables.cfm= evidence,life,life_tables&language=english (last accessed 16.6.2005).
6. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321: 405-412
7. Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br Med J 2000; 321: 412-419
8. National Institute for Clinical Excellence (NICE) - Guide to the Methods of Technology Appraisal (2004). http://www.nice.org.uk/pdf/ TAP_Methods.pdf (last accessed: 1.6.2005).
9. van Hout BA, Al MJ, Gordon GS et al. Costs, effects and C/E-ratios alongside a clinical trial. Health Economics 1994; 3: 309-319
10. American Diabetes Association Consensus Panel. Guidelines for Computer Modeling of Diabetes and Its Complications. Diabetes Care 2004; 27: 2262-2265
11. Analytica International. EAGLE technical documentation: Auf Anfrage erhältlich.
12. Bergemann R. Charakteristika valider Health-Outcomes Modelle. Gesundh ökon Qual manag 2005; (Suppl 2): S59-S63
13. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1995; 122: 561-568
14. Moss SE, Klein R, Klein BE. The prevalence and incidence of lower ex-tremity amputation in a diabetic population. Arch Intern Med 1992; 152: 610-616
15. Eastman RC, Javitt JC, Herman WH et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 1997; 20: 725-734
16. Eastman RC, Javitt JC, Herman WH et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997; 20: 735-744
17. Colhoun HM et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696